We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+139.15%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$208M
Cap. Flow
+$91.8M
Cap. Flow %
12.61%
Top 10 Hldgs %
81.82%
Holding
47
New
5
Increased
2
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$65.5M
2
UPB
Upstream Bio Inc
UPB
+$49.5M
3
NGNE icon
Neurogene
NGNE
+$16.7M
4
OKUR
OnKure Therapeutics
OKUR
+$12.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.3M
2
ACLX
Arcellx
ACLX
+$8.64M
3
LENZ
LENZ Therapeutics
LENZ
+$6.75M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$3.84M
5
IOBT
IO Biotech
IOBT
+$3.82M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Financials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
26
Sutro Biopharma
STRO
$421M
$4.04M 0.55%
219,681
– –
ARTV
27
Artiva Biotherapeutics
ARTV
$551M
$2.94M 0.4%
291,666
– –
VTVT icon
28
vTv Therapeutics
VTVT
$139M
$2.86M 0.39%
206,784
– –
TNGX icon
29
Tango Therapeutics
TNGX
$4.41B
$1.95M 0.27%
630,000
– –
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$1.87M 0.26%
147,319
– –
IMTX icon
31
Immatics
IMTX
$1.32B
$1.41M 0.19%
198,000
– –
PRME icon
32
Prime Medicine
PRME
$559M
$1.18M 0.16%
405,228
-135,076
-25% -$474K
TERN
33
DELISTED
Terns Pharmaceuticals
TERN
$1.12M 0.15%
202,348
– –
HLVX
34
DELISTED
HilleVax
HLVX
$827K 0.11%
399,637
-399,637
-50% -$750K
CRIS icon
35
Curis
CRIS
$7.83M
$607K 0.08%
+9,911
New +$850K
JANX icon
36
Janux Therapeutics
JANX
$967M
$603K 0.08%
11,263
-11,263
-50% -$596K
BOLT icon
37
Bolt Biotherapeutics
BOLT
$7.78M
$561K 0.08%
52,458
– –
LYRA
38
DELISTED
LYRA THERAPEUTICS INC
LYRA
$406K 0.06%
39,314
-16,291
-29% -$179K
ALLK
39
DELISTED
Allakos
ALLK
$208K 0.03%
172,089
– –
KRON
40
DELISTED
Kronos Bio
KRON
$74.2K 0.01%
78,131
– –
KLRS
41
Kalaris Therapeutics
KLRS
$96.8M
$34.6K ﹤0.01%
3,580
– –
NUVB.WS
42
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$30.7K ﹤0.01%
133,333
– –
SRZNW icon
43
Surrozen Inc Warrant
SRZNW
$8.86K
$2.14K ﹤0.01%
99,999
– –
IOBT
44
DELISTED
IO Biotech
IOBT
– –
-3,640,015
Closed -$3.82M
BCAX
45
Bicara Therapeutics
BCAX
$1.84B
– –
-35,000
Closed -$891K
SYRS
46
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-1,786,427
Closed -$3.84M
VIRX
47
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-689,709
Closed -$160K
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2024 Portfolio in Review

As of Q4 2024, Samsara BioCapital held 47 positions worth $729M, up 40% from $520M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Samsara BioCapital deployed $91.8M of net new capital in Q4 2024, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Septerna Inc: 2,768,520 shares worth $63.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Scholar Rock, an estimated $38.3M trimmed.

  • Samsara BioCapital's largest Q4 2024 buy was Septerna Inc: 2,768,520 shares worth $63.4M.
  • Samsara BioCapital added most to Neurogene in Q4 2024, an estimated $16.7M increase.
  • Samsara BioCapital's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $38.3M.
  • Samsara BioCapital fully exited Syros Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $3.84M.
  • Samsara BioCapital's ten largest holdings make up 82% of its $729M portfolio in Q4 2024.
  • Samsara BioCapital opened 5 new positions and closed 4 in Q4 2024.
  • Samsara BioCapital's portfolio value rose 40% quarter-over-quarter to $729M.

Based on Samsara BioCapital's 13F filing for Q4 2024, filed 14 Feb 2025.